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INTRODUCTION 
Hydroxychloroquine is an aminoquinolines that has 
received much attention during the current 
coronavirus pandemic. It is an approved drug for the 
treatment of systemic lupus erythematosus, 
rheumatoid arthritis and malaria, discoid lupus 
erythematosus, polymorphic light eczema and 
juvenile idiopathic arthritis. Contraindications to 
treatment with HCQ include existing retinopathy, 
visual field defects, porphyria, hypersensitivity to 
HCQ, auditory nerve damage and psoriasis. 
Hydroxychloroquine is well absorbed in oral 
administration. The half-life in the blood is very long, 
about 30-50 days. The degree of binding to proteins 
in plasma is relatively low, around 40 percent. It 
accumulates in certain tissues, including retina, 
muscles, and erythrocytes. Elimination takes place 
mainly via the kidneys.   
 
Literature data suggests that it influences viral 
replication of SARS-CoV-2 (1, 2). In these studies, 
treatment regimens of 400 to 600 mg of 
hydroxychloroquine/day for 5 to 10 days are 
suggested.1,2 Knowledge of toxicity and serious side 
effects mainly comes from retrospective studies and 
case reports.3 The randomized controlled trials that 
exist are small and have a narrow selection of 
participants, where patients with, for example, high 
age and comorbidities are often excluded.3 These 
factors make it difficult to know the exact frequency 
of serious side effects when using 
hydroxychloroquine in clinical practice. 
 
 
 
In view of the potential massive use of 
hydroxychloroquine in the treatment of COVID-19, a 
review on safety of hydroxychloroquine was  
conducted. The relevant publications found were 
assessed by both the authors, and additional 
information in the literature references of each 
publication was sought. 
 
Against COVID-19, HCQ has an indirect mechanism 
of action, related to the inflammatory response to the 
virus. Inhibition of inflammatory mediators such as 
the tumor necrosis factor alpha and its receptor, and 
interleukin 6, causes discontinuation in the cascade 
of immune response to the virus, such as endothelial 
and alveolar patency, and therefore nearly two 
decades ago it was proposed that it would have a 
potential benefit in the prevention and treatment of 
acute respiratory distress caused by coronavirus.4 
 
The literature describes interactions with beta-
blockers with hepatic metabolism, amiodarone, and 
digoxin.5 In patients with systemic lupus 
erythematosus, it was verified that CYP2D6 
polymorphisms correlate with the serum drug levels, 
and this would be relevant in relation to the 
treatment of COVID-19: It is possible that patients 
treated with similar doses have disparate results 
according to the type of CYP2D6 polymorphism they 
have. (6) With the information available so far, some 
regulations on COVID-19 treatment with HCQ do not 
recommend the concomitant  use of  amiodarone and  
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suggest monitoring both digoxin blood levels and the 
QT interval. 
 
Meanwhile, in patients receiving HCQ, the 
combination of increasing doses of azithromycin 
increases the QT interval. This must be highlighted in 
view of the potential combined use of both drugs in 
current clinical trials for COVID-19.7,8  
 
In a systematic review describing cardiovascular 
complications in patients with rheumatic diseases, 
disturbance in the conduction system, ventricular 
hypertrophy, alterations in left ventricular wall 
motion, symptomatic heart failure, pulmonary 
arterial hypertension, and valve dysfunction were 
reported on use of chloroquine and HCQ and the 
recovery rate after discontinuation was only around 
45%.9 Serious side effects that may occur as a result of 
a short period of treatment with hydroxychloroquine. 
One known long-term side effect is, retinopathy, 
which occurs as a result of tissue accumulation in 
melanin-containing cells. 
 
A systematic review found publications of patients 
who on HCQ developed a specific cardiomyopathy, 
with granular inclusions with vacuolation of the 
cardiomyocytes, intravacuolar lamellar bodies, or 
curvilinear bodies. It is speculated that these lesions 
are attributed to a lysosomal effect, and some authors 
have described it as a phenocopy of Anderson-Fabry 
disease. Cardiomyopathy may cause hypertrophy and 
restrictive behavior. In most cases it manifests as 
clinical heart failure, or as alterations of the 
conduction system, and syncope. Approximately half 
of patients develop ventricular dsyfunction and 
mortality is 45%. The chronic use of HCQ could then 
be the direct but extremely rare cause of an acquired 
lysosomal storage disease.10 
 
In a review of electrocardiographic findings of 
patients with rheumatic diseases treated chronically 
with HCQ, normal PR, QRS, QTc values were 
observed, with only two cases of complete right 
bundle branch block and one case of left bundle 
branch block. However, this study has limitations, 
including not having baseline studies to make 
comparisons.11 Tachycardia secondary to 
vasodilatation has been observed. Capel RA et al., in 
animal models, verified that HCQ causes 
bradycardia.12 However, in humans the heart rate 
could increase by indirect mechanisms. There are 
cases   of  HCQ-induced     QT   prolongation   in   the  
literature. hydroxychloroquine affects the 
repolarisation of myocardial cells and extend the QTc 
interval. This increases the risk of potentially lethal 
ventricular arrhythmias, such as Torsades de pointes. 
The prolongation of the QTc interval is dose-
dependent and usually occurs shortly after the first 
dose.13 It is important to consider the patient’s overall 
risk factors for QTc prolongation and Torsade de 
pointes in treatment with hydroxychloroquine. 
Significant risk factors include high age, heart 
disease, certain electrolyte imbalances and 
concomitant treatment with multiple drugs that 
cause QTc prolongation.14,15 Most of these factors are 
also risk factors for severe COVID-19 infection.16 A 
non-randomised study reported that 
hydroxychloroquine in combination with 
azithromycin has an effect on COVID-19.2 Both 
hydroxychloroquine and azithromycin can prolong 
QTc.17 In a preliminary report, worrying QTc 
prolongations are reported in combination therapy 
with hydroxychloroquine and azithromycin for 
COVID-19.18 
 
Hydroxychloroquine can rarely cause very serious 
skin reactions like Stevens-Johnson syndrome, toxic 
epidermal necrolysis and Drug reaction with 
eosinophilia and systemic symptoms. These 
conditions usually occur one to four weeks after 
starting treatment and can have a fatal outcome.19-21 
Hydroxychloroquine may also result in outbreaks of 
psoriasis and should not be used in the presence of 
known psoriasis. Hydroxychloroquine can cause 
severe hypoglycaemia.22 The mechanism of 
hypoglycaemia is believed to be increased release of 
insulin from pancreatic beta cells as well as decreased 
degradation of insulin, which together causes 
hyperinsulinemic hypoglycaemia.23 In case of severe 
hypoglycaemia, treatment with 4-aminoquinolines 
should be discontinued immediately and glucose 
should be administered. Lastly, it is possible that 
when dealing with the massive use of HCQ cases of 
intoxication and overdose with these drugs may 
occur. In this sense, hypotension, conduction 
alterations and hypokalemia must be considered as 
primary findings.  
 
CONCLUSION 
Hydroxychloroquine have been proposed as a therapy 
candidate in COVID-19. Some patients suffer from 
serious side effects when treated with HCQ, such as 
hypotension, tachycardia, mild and asymptomatic QT 
prolongation, greater QT prolongation in 
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concomitant treatment with azithromycin, 
interactions with amiodarone, digoxin, and beta-
blockers, hypoglycemia and severe skin reactions. 
Ideally, it should only be used in accordance with 
approved indications or within clinical trials. More 
and larger randomized trials with adequate study 
protocols are required before any conclusions can be 
drawn on the efficacy and safety of COVID-19 
therapy. It is still unclear when COVID-19 pandemic 
would end, and still a definite treatment is lacking. 
Therefore, the health care professionals do not have 
much management choices for coronavirus infection. 
So, hydroxychloroquine should be prescribed only 
after weighing the benefits and risks of this dug. 
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